

ICAN Summit - Orlando 2017

Please follow us on Twitter @eYPAGnet

WHY eYPAGnet? External reasons

- Specific environment to regulate the development of new treatments in Europe. Different from FDA or others.
- EMA has established a framework to involve the young patients in their activities.
- Creation of the Pan-European Network of Paediatric Clinical Trials (IMI2 Project). 2018-2023
- Increase the collaboration among European YPAG: all the paediatric clinical trials are international.



WHY eYPAGnet? Internal reasons

- Improve collaboration with different stakeholders.
- Gather examples of best practice and promote research in the field of young patients advocacy.
- Consolidate the European curriculum of capacity-building and empowerment training programs to the young patients.
- Europe's ICAN SOP to promote and lead the creation of new chapters.
- Create a common portfolio of YPAG's services addressed to the stakeholders: White Paper.

WHERE are we?



Team in process



WHAT are we going to do?

Informed groups

Training in clinical research

Scientific meetings

Single point of contact

Coordination at European level Business model for sustainability